Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study. - Wikidata - wikimedia - TriplyDB

Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.

Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.

http://www.wikidata.org/entity/Q33953840

about

Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design Expression and function of phosphodiesterases (PDEs) in the rat urinary bladder.Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.The role of phosphodiesterases in bladder pathophysiology.Next generation modeling in GWAS: comparing different genetic architectures.Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice.Phosphodiesterase 9 (PDE9) regulate bovine tracheal smooth muscle relaxation.Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005.

P2860

Q27673292-5BE4B880-C596-49B9-807E-00968A1CA14B Q33884158-246D7459-C3C7-4CC7-98CA-241111B603D8 Q35924409-40D23851-68ED-45F1-A6B5-B7F234C1E432 Q38106628-8BAA72F0-3FAF-44CC-A3BF-8C4CF9AB4189 Q42666413-27780D92-9766-4E1D-B950-A50DFED430D5 Q45904083-8A2848A3-704F-4C93-9CE5-ADC004218BE2 Q49544797-A3E7C4A2-DE3E-45C8-89B6-1502E7ABFECD Q51640625-C5BB9F5A-E3A9-477B-A17D-B9040336F6B2

P2860

Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.

http://www.wikidata.org/entity/Q33953840

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@ast

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@en

type

label

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@ast

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@en

prefLabel

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@ast

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@en

P1433

Q33953840-7D85F173-8EB6-40D5-9B10-CEB3C302E41D

P1476

Q33953840-4DEF4233-6150-401D-8C3B-E3C43C5C9502

P2093

Q33953840-1EE62874-62C5-4CCA-A9AA-6D1C40F548F5

Q33953840-3A33E6ED-DD40-47A3-8431-9C25985DA13C

Q33953840-3EAE5FA6-545D-4C16-B6EF-417483547EDC

Q33953840-3F073B51-A70A-4393-8056-1441950050C0

Q33953840-901DE15F-22A3-4106-B2B9-0587D91BE01B

Q33953840-A2CC5CD4-03CB-48CD-AAB8-71DC490FAE69

Q33953840-FE2BDF4C-7F56-4956-A279-8AADC2EF2724

P2860

Q33953840-034D5083-3C75-4094-BE7B-AFC16616B680

Q33953840-13F5E0C2-BD06-443C-BC46-48B89AF8B836

Q33953840-1EBEEAF9-2FD0-4AB5-B266-EF9C2576D829

Q33953840-30F33981-2880-48F5-AFC6-644F0E57ED0C

Q33953840-37848E3A-BC04-4F99-90B0-56D9087570C4

Q33953840-39F011D7-A47C-4379-8278-5B194CAD8DB1

Q33953840-4A2B5689-6B07-4B58-88E9-0D57B768B496

Q33953840-53D5AB91-A38F-4F6A-A734-5239306D3C69

Q33953840-623DBB3B-58A7-4FBD-AD56-E01DC8EB7D3B

Q33953840-778631B6-4917-404B-B329-B2F03538A066

P304

Q33953840-1A0C973F-E6A2-4A13-B513-11D0E4BF7759

P31

Q33953840-F7E75345-738F-47CD-B8FF-E85BC436336E

P356

Q33953840-87326897-1A49-4E36-B3F8-E279651D48FF

P433

Q33953840-C6750D01-EA63-4C95-A5F2-9EA495B6F9A9

P478

Q33953840-029B6BC2-A110-447F-98AD-0B0DAB1B9407

P577

Q33953840-E83E5F40-EFD5-4F24-8023-3EC19BF98D52

P698

Q33953840-6A0B9E7F-CA81-4A77-B1DE-169EB3A920F1

P921

Q33953840-C64CC5A6-D454-45CC-B389-EE750E91DD4B

P356

J.1464-410X.2011.10429.X

P1433

BJU International

P1476

Phosphodiesterase type 9 (PDE9 ...... an immunohistochemical study.

@en

P2093

Hironobu Sasano

http://www.w3.org/2001/XMLSchema#string

Katsuhiko Ono

http://www.w3.org/2001/XMLSchema#string

Mariko Masuda

http://www.w3.org/2001/XMLSchema#string

Shuji Nagasaki

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Miki

http://www.w3.org/2001/XMLSchema#string

Youichi Nakano

http://www.w3.org/2001/XMLSchema#string

Yukiko Shibahara

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder.

Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene.

Muscarinic receptor antagonists for overactive bladder.

Storage and voiding symptoms: pathophysiologic aspects.

Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.

P304

934-940

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2011.10429.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21736695

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry